¿Ha cambiado el paradigma de la prevención del ictus en los pacientes con diabetes? / Has the paradigm of stroke prevention changed in patients with diabetes?

No disponible

Utilidad de los modelos predictivos de embolia pulmonar / Usefulness of predictive models of pulmonary embolism

ANTECEDENTES: Ante la sospecha de embolia pulmonar (EP), las guías recomiendan el empleo de escalas de probabilidad clínica, medición del dímero D y, en determinados casos, confirmar mediante angiografía pulmonar mediante tomografía computarizada (APTC) o gammagrafía. Recientemente se ha planteado ajustar el dímero D según edad o usar escalas más sencillas (algoritmo YEARS) para una mejor selección de los pacientes. OBJETIVO: Definir el grado de aplicación de las guías en nuestra población y comparar sensibilidad, especificidad y valores predictivos positivo y negativo de los diferentes modelos diagnósticos: modelo estándar (Wells 2 categorías+dímero D), modelo ajustado por edad (Wells 2 categorías+dímero D ajustado por edad), algoritmo YEARS. MATERIAL Y MÉTODOS: Estudio retrospectivo de todos los pacientes que se sometieron en nuestro centro a APTC para diagnóstico de EP durante un año. RESULTADOS: De 618 casos (el 85,4% de las APTC) iniciales se incluyeron 544 pacientes. Se diagnosticaron 113 EP (20,8%). El grado de aplicación del modelo estándar fue muy alto (90,1%) y demostró presentar la mejor relación sensibilidad y valor predictivo negativo (sensibilidad=1, valor predictivo negativo=1). Los nuevos modelos podrían reducir el número de exploraciones (17; 3,2% modelo ajustado por edad y 48; 8,8% modelo YEARS) con riesgo de falsos negativos (2 EP [1,8%] no diagnosticadas respectivamente). CONCLUSIONES: Los modelos diagnósticos actuales para EP llevan a la realización de un gran número de exploraciones innecesarias. Los nuevos modelos podrían reducir el número de APTC aunque con un mínimo riesgo de falsos negativos

BACKGROUND: Faced with the suspicion of pulmonary embolism (PE), the guidelines recommend the use of clinical probability scales, measurement of D-dimer and, in certain cases, confirmation by pulmonary angiography by computed tomography (CTPA) or scintigraphy. Recently, it has been proposed to adjust the D-dimer according to age or use simpler scales (YEARS algorithm) for a better selection of patients. OBJECTIVE: To define the degree of application of the guidelines in our population and compare sensitivity, specificity and positive and negative predictive values of the different diagnostic models: Standard model (Wells 2 categories+D-dimer), Model adjusted for age (Wells 2 categories+D-dimer adjusted for age), YEARS algorithm. MATERIAL AND METHODS: A retrospective study of all patients who underwent APTC at our centre for the diagnosis of PE over one year. RESULTS: Of 618 cases (85.4% of initial APTC), 544 patients were included. A total of 113 EPs were diagnosed (20.8%). The degree of application of the standard model was very high (90.1%) and proved to have the best sensitivity and negative predictive value ratio (sensitivity=1.0, negative predictive value=1.0). The new models could reduce the number of scans (17, 3.2% model adjusted for age and 48, 8.8% model YEARS) with a risk of false negatives (2 PE [1.8%] undiagnosed respectively). CONCLUSIONS: The current diagnostic models for PE lead to a large number of unnecessary explorations. The new models could reduce the number of APTC although with a minimum risk of false negatives

Pharmacological management of post-stroke depression.

Introduction: Post-stroke depression (PSD) is a common clinical problem affecting approximately one-third of stroke survivors. PSD is associated with poor functional outcome and higher morbidity and mortality rates. Currently, uncertainty remains regarding optimal pharmacological strategies for its prevention and treatment.Areas covered: This article reviews the state of the current literature on pharmacologic intervention strategies for PSD, providing a summary of the most recent evidence to support pharmacological treatment in PSD.Expert opinion: Experimental and clinical research have increased our knowledge on PSD, although unanswered questions still remain regarding the best time to begin treatment, the effect of the antidepressants in areas other than emotion, or their capability to reduce mortality in stroke patients, among others.Currently, though numerous trials and meta-analyses suggest that antidepressants are effective in treating PSD and guidelines recommend their use for PSD, in the daily clinical practice, only a minority of patients are properly assessed and treated. Therefore, though further evidence is needed to clarify the real role of antidepressants in patients with stroke, physicians and other healthcare professionals must be familiar with the pharmacological treatment of PSD, in order to improve the outcome and increase the quality of life of this vulnerable group of patients.

Usefulness of predictive models of pulmonary embolism. / Utilidad de los modelos predictivos de embolia pulmonar.

BACKGROUND: Faced with the suspicion of pulmonary embolism (PE), the guidelines recommend the use of clinical probability scales, measurement of D-dimer and, in certain cases, confirmation by pulmonary angiography by computed tomography (CTPA) or scintigraphy. Recently, it has been proposed to adjust the D-dimer according to age or use simpler scales (YEARS algorithm) for a better selection of patients. OBJECTIVE: To define the degree of application of the guidelines in our population and compare sensitivity, specificity and positive and negative predictive values of the different diagnostic models: Standard model (Wells 2 categories+D-dimer), Model adjusted for age (Wells 2 categories+D-dimer adjusted for age), YEARS algorithm. MATERIAL AND METHODS: A retrospective study of all patients who underwent APTC at our centre for the diagnosis of PE over one year. RESULTS: Of 618 cases (85.4% of initial APTC), 544 patients were included. A total of 113 EPs were diagnosed (20.8%). The degree of application of the standard model was very high (90.1%) and proved to have the best sensitivity and negative predictive value ratio (sensitivity=1.0, negative predictive value=1.0). The new models could reduce the number of scans (17, 3.2% model adjusted for age and 48, 8.8% model YEARS) with a risk of false negatives (2 PE [1.8%] undiagnosed respectively). CONCLUSIONS: The current diagnostic models for PE lead to a large number of unnecessary explorations. The new models could reduce the number of APTC although with a minimum risk of false negatives.

Statins in Stroke Prevention: Present and Future.

BACKGROUND: Over the last decades, the reduction of the mortality and morbidity of stroke has been a high- priority objective worldwide. Statins, or 3-hydroxy-3- methylglutaryl coenzyme A (HMG- CoA) reductase inhibitors, have emerged as the predominant preventive strat egy to tackle the worldwide stroke burden. Currently, statins are considered the most important advance in stroke prevention since the introduction of aspirin and antihypertensive treatments. METHODS: In this paper we review the current evidence regarding the role of statins in the stroke prevention and future directions in this field. RESULTS: A meta-analysis of random ised trials of statins has shown that each 1 mmol/L (39 mg/dL) decrease in low-density lipoprotein cholesterol, equates to a reduction in relative risk for stroke of 21.1%. Statins are now recommended for the primary prevention of ischemic stroke in patients estimated to have a high 10-year risk for cardiovascular events. Nevertheless, until recently there was little evidence that statin therapy reduced the risk of stroke recurrence. The SPARCL, published in 2006, was the first trial to show the benefits of statin therapy in preventing recurrent stroke. Now we know that statins reduce the risk of stroke recurrence by 12-16% and statins are recommended among patients with ischemic stroke or TIA presumed to be of atherosclerotic origin or with other comorbid atherosclerotic cardiovascular disease. CONCLUSION: Traditionally, there has been no clear data demonstrating that adding other lipid-modifying drugs to statins results in a further decrease in stroke or other cardiovascular event, but now things have changed and future directions include combinations with ezetimibe and new treatments such as PCSK9 inhibitors. Only time will tell the real roll of these new promising non-statin lipidmodifying therapies on stroke prevention.